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OBJECTIVE: To evaluate the effectiveness of the treatment of acromegaly patients at the Federal University of
Triangulo Mineiro.
METHODS: Cross-sectional and retrospective study of thirty cases treated over a period of two decades.
RESULTS: 17 men (56.7%) aged 14-67 years and 13 women aged 14-86 years were analyzed. Twenty-one patients
underwent transphenoidal surgery, whichwas associated with somatostatin receptor ligands in 11 patients
(39.3%), somatostatin receptor ligands + radiotherapyin 5 patients (17.8%), radiotherapy in 3 patients (10.7%),
and radiotherapy + somatostatin receptorligands + cabergoline in 1 patient (3.6%). Additionally, 2 patients
underwent radiotherapy and surgeryalone. Six patients received somatostatin receptor ligands before surgery,
and 2 were not treated due to refusal and death. Nine patients have died, and 20 are being followed; 13 (65%)
have growth hormonelevels o1 ng/mL, and 11 have normal insulin-like growth factor 1 levels.
CONCLUSION: The current treatment options enable patients seen in regional reference centers to achieve strict
control parameters, which allows them to be treated close to their homes.
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’ INTRODUCTION
Classically described as a rare disease (1), acromegaly has
an estimated prevalence of 36-60 cases/million persons and
an annual incidence of 3-4 cases/million persons, and its
incidence triples among adults aged 65 years and older (2,3).
Men and women are similarly affected, and the most com-
mon cause is a growth hormone (GH)-secreting pituitary
macroadenoma (1-3).
The diagnosis of acromegaly is based on findings such as
panhypopituitarism, neuro-ophthalmic symptoms and signs
due to compression of adjacent structures as the tumor grows
and confirmed by increased GH and insulin-like growth
factor 1 (IGF-1) levels, non-suppression of GH during an
oral glucose tolerance test (OGTT) and magnetic resonance
imaging of the sella turcica (1,2,4).
Treatment of acromegaly is considered effective when patients
achieve basal plasma GH levels below 1 ng/mL or glucose-
suppressed GH levels below 0.4 ng/mL and normal IGF-1
levels (5-7). Currently, these hormonal control targets can
only be achieved by following a treatment plan consisting
of tumor ablation either preceded or followed by pharma-
cological treatment with increasing individualized doses
of somatostatin receptor ligands (SRLs) and, in some cases,
dopamine receptor agonists and GH receptor antagonists
(4,8-10). Radiotherapy is a third-line treatment and should
be performed when surgery and drug therapies are not
effective or when aggressive tumors invade the surround-
ing structures (4,6-10).
The treatment of acromegaly has evolved considerably over
the past three decades (11), allowing patients to be treated
outside the major referral centers in Brazil. The objective of
this study was to report our experience with patients with
acromegaly or gigantism who were treated at the Federal
University of Triângulo Mineiro (Universidade Federal do
Triângulo Mineiro – UFTM) and to evaluate the effective-
ness of treatment and the outcomes of these patients.
UFTM is located in Uberaba, a medium-sized city in the
state of Minas Gerais, Brazil. The patients outcomes were
evaluated according to the hormonal and metabolic controlDOI: 10.6061/clinics/2017(04)05
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criteria currently established in the literature (4-7). The
most common co-morbidities and complications were also
analyzed.
’ SUBJECTS AND METHODS
This retrospective study was approved by the Research
Ethics Committee of UFTM and was conducted by the Depart-
ments of Neurosurgery and Endocrinology.
The medical records of patients with acromegaly and gigan-
tism who were treated in these departments were analyzed.
The medical records were actively searched, and a summary
was completed for each case. The summary included the
patient’s clinical history with signs and symptoms reported
by the patient, the results of a standardized diagnostic
investigation performed at the Department of Endocrinology,
a description of treatments performed and their complica-
tions, a description of the evolution of GH and IGF-1 levels
during treatment and of the control of adenohypophyseal
hormone levels at diagnosis and during replacement therapy,
the presence, treatment and control of metabolic complica-
tions such as diabetes, hypertension and dyslipidemia and
references to cardiorespiratory, joint, and gastrointestinal
complications, thyroid diseases and cancer. The medical
records of deceased patients and the causes of their deaths
were also analyzed.
The effectiveness of treatment was analyzed according to
the strict control criteria recommended by the consensus
described in the literature: basal baseline serum concentra-
tions of GH o1 ng/mL or GH o0.4 ng/mL during to a
glucose tolerance test and IGF-1 o two standard deviations
(SD) from the mean for age and gender (6,7).
Over a 23-year period, 27 patients with acromegaly and
3 with gigantism were diagnosed. These individuals were
divided into group 1 (G1), which consisted of 17 men (56.7%)
and group 2 (G2), which consisted of 13 women (43.3%).
The overall male-female ratio of the patients in the study
was 1.3:1; their ages at diagnosis ranged from 14 to 67 years
(median 45.5 years) and from 14 to 86 years (median
47.5 years) for males and females, respectively.
Statistical analysis
Anthropometric data and hormone concentrations are pre-
sented as median, minimum and maximum values. Student’s
t-test was used to compare the age and body mass index
(BMI) of females and males at diagnosis. Friedman’s test
followed by Dunn’s multiple comparison test was used
to compare the patients’ GH and IGF-1 levels during
the treatment stages. The Mann-Whitney U test was used
to compare the GH levels measured in the last clinical
evaluation between patients who underwent surgery +
radiotherapy + SRLs and those who underwent surgery +
SRLs. Spearman’s test was used for correlations between
GH levels before treatment and GH levels after surgery
or after radiotherapy, and between GH basal values and
current GH values of patients treated with surgery +
radiotherapy + SRLs and among patients who received
surgery +SRLs. P-values less than 0.05 were considered
significant.
’ RESULTS
Of the 30 patients, 27 had excessive GH production due to
macroadenomas, and 3 patients had excessive GH production
caused by microadenomas. After diagnosis, 1 patient refused
surgical or medical treatment. For the remaining 29 patients,
the follow-up period ranged from 4 months (newly diagnosed
patients) to 23 years (mean 9 years). During this period,
9 patients died, and 20 remained on routine follow-up.
The BMI of the G1 and G2 groups ranged from 17.6 to
53.4 kg/m2 (median 28.4) and from 25.5 to 29.8 kg/m2
(median 27.8), respectively. Of the total, 25 patients had BMIs
indicating overweight (n=18) or obesity (n=7). No significant
differences were observed between men and women regard-
ing age at diagnosis (p=0.973) or BMI (p=0.425) (Table 1).
The majority of the patients were from Uberaba (n=15) or
municipalities of the Triângulo Sul region (n=12). These
regions are covered by the Clinics Hospital/UFTM for highly
complex procedures through the Unified Health System
(Sistema Único de Saúde - SUS) (12). Three patients were
from São Paulo state and lived in towns bordering the state
of Minas Gerais.
The mean time to diagnosis was 4 years and ranged from
at the first doctor visit to 20 years. Most patients reported
symptoms/signs classically associated with acromegaly
(Table 2).
Initial laboratory tests indicated GH levels ranging
from 8.0 to 355.0 ng/mL (median 25.6 ng/mL) and IGF-1
levels (analyzed according to age group) between 105.0 and
Table 2 - Clinical symptoms and signs obtained from medical
records and frequently reported by acromegaly patients at
diagnosis.
Clinical feature G1 (n=17) G2 (n=13) Total
(n=30) %
Acral overgrowth 15 12 27 90.0
Bone and muscle pain 11 6 17 56.7
Headaches 11 5 16 53.3
Visual field deficits 5 6 11 36.7
Weight gain 4 5 9 30.0
Nasal obstruction/sinusites 6 3 9 30.0
Edema/skin thickening 4 4 8 26.7
Constipation 3 4 7 23.3
Adynamia 2 5 7 23.3
Voice deepening 4 2 6 20.0
Amenorrhea / Galactorrhea – 6 6 20.0
Impotence 4 – 4 13.3
Tall stature 2 1 3 10.0
Table 1 - Clinical data of patients with acromegaly and
gigantism.
Parameter G1 (n=17) G2 (n=13) Total (n=30)
Age at diagnosis
(yrs., mo.)
#45.5 (a)
(14.0 – 67.0)
47.5 (a)
(14.0 – 86.0)
46.0
(14.0 – 86.0)
Weight (kg) 87.3
(64.3 – 199.0)
71.2
(64.4 – 89.0)
-
Height (m) 1.77
(1.63 – 1.94)
1.59
(1.55 – 1.77)
-
BMI (kg/m2) 28.4 (b)
(17.6 – 53.4)
27.8 (b)
(25.5 – 29.8)
29.0
(17.6 – 53.4)
Follow-up period (yrs.) 10.0
(1.0 – 20.0)
7.0
(0.4 – 23.0)
9.0
(0.4 – 23.0)
#Data are expressed as median (minimum and maximal values)
Student’s t-test
a: p=0.973
b: p=0.425.
219
CLINICS 2017;72(4):218-223 Acromegaly treatment at UFTM
Borges MF et al.
1321.0 ng/mL (median 707.5 ng/mL). Four patients (1 man
and 3 women) had mixed GH- and prolactin-secreting tumors.
The therapeutic approach is shown in Table 3. The treat-
ment approaches were individualized to achieve the control
criteria. One male patient who refused treatment and
1 female patient diagnosed at age 86 who died in the first
months of follow-up are not included in the treatment
table. Transphenoidal adenomectomy was the first approach
for most patients (21/28, 75%). Complementary radio-
therapy was offered to patients up to the 1990s, and
9 patients received it. One patient underwent radiotherapy
alone and another patient underwent surgery alone and
achieved clinical control.
When SRL began to be provided by the SUS, its admini-
stration became the main approach used to complement
surgery. SRL was initially administered subcutaneously
(100 mg every 8 hours), and beginning in the 1990s, all
patients received octreotide LAR (Novartiss). Over the
past year, 3 patients used lanreotide (Ipsens) due to poor
adherence to medication.
Of the 28 patients, 17 (60.7%) received clinical treatment
after surgery, and 6 patients (21.4%) received clinical treat-
ment prior to surgery. Four patients who presented elevated
prolactin levels were also treated with cabergoline (Pfizers).
Of the 21 patients who underwent surgery, only 1 patient
did not require therapeutic complementation to achieve
the clinical control criteria. For the other 20 patients, the
reduction in the absolute and percent GH levels compared to
the baseline value at diagnosis was analyzed. This analysis
could not be performed for IGF-1 levels due to missing
baseline values (Table 4).
Surgery resulted in a 12.7-83.0% (median 53.0%) reduction
in basal GH levels, but there was no significant difference
between GH levels before and after surgery (p40.05). GH
levels were reduced by 14.0-96.8% (median 87.7%) among
patients who underwent radiotherapy after surgery (n=9),
but no significant difference was observed between GH
levels at baseline and post-surgery (p40.05). Six of these
patients were treated with SRLs, and a significant reduction
in GH levels was observed (po0.05), with percent changes
ranging from 90.4 to 99.5% (median 98.7%) (Table 4).
In 11 cases, surgical treatment was complemented only
with SRLs. In these patients, GH levels were reduced by
65.0-99.9% (median 95.2%) compared to baseline levels, and
the reduction was significant (po0.05). When the reduction
in GH level was compared between therapeutic modalities,
no differences were observed at the end of treatment between
surgery + radiotherapy + SRLs and surgery + SRLs
(p40.05). However, the reductions achieved with surgery +
SRLs were significant compared to surgery + radiotherapy
(Table 4).
No significant correlation was found between the pre-
treatment and current GH and IGF-1 levels among patients
who received surgery + radiotherapy + SRLs, or among
those who received surgery + SRLs. A positive and signi-
ficant correlation was observed between pretreatment GH
levels and postsurgical GH levels, as well as between pre-
treatment GH levels and GH levels after surgery + radio-
therapy (Figure 1).
Nine deaths occurred during the follow-up period, and 20
patients remain on routine follow-up. The treatment mod-
alities of the remaining patients are shown in Table 5; surgery
followed by clinical treatment was the main treatment
approach and clinical treatment was also provided while
the patient awaited surgery.
A recent evaluation revealed that the strict control criteria
were met in 11/20 of the remaining patients (55.0%)
(Table 6). In 2 cases, baseline GH levels were less than
1.0 ng/mL, with IGF-1 42 SDs above the mean for age and
gender. Two female patients with GH41.0 ando2.5 ng/mL
had levels near the control target. Among the patients with
GH 42.5 and elevated IGF-1, 3 male patients had post-
operative recurrence, and 2 were recently diagnosed and are
being primarily treated with SRLs.
Among the deceased patients (n=9), the age at death was
44-87 years (median 54 years), and the follow-up period
was 1-23 years (median 6 years). Of these patients, only
2 had GH/IGF1 levels that met the strict control criteria.
Six patients died due to infections (bronchopneumonia and
urinary tract infections), 2 died due to cardiovascular events
(acute myocardial infarction and pulmonary embolism), and
1 patient died due to breast cancer.
Co-morbidities and complications
In addition to the overweight and obesity mentioned
previously, 30 patients had other co-morbidities: 11 patients
(36.7%) presented impaired fasting glucose, 7 patients
(23.3%) had diabetes, and 7 patients developed diabetes
Table 4 - Decrease in serum growth hormone concentrations
[GH] from pretreatment values in patients who received
different modalities of treatment.
Treatment performed k [GH] ng/mL k [GH] %
Pretreatment GH(a) (n=21) 25.6 (8.0 – 355.0) –
After surgery (b) (n=21) 14.5 (1.5 – 310.0) 53.1 (12.7 – 83.0)
Surgery + RT (c) (n=9) 8.10 (1.6 – 79.2) 87.7 (14.0 – 96.8)
Surgery + RT + SRLs (d) (n=6) 0.7 (0.3 – 8.7) 98.7 (90.4 – 99.5)
Surgery + SRLs (e) (n=11) 0.6 (0.2 – 7.9) 95.2 (65.0 – 99.9)
RT= radiotherapy; SRLs= somatostatin receptor ligands
Friedman’s test followed by Dunn’s test
a x b = p40.05 (n=21)
a x b x c = p40.05 (n=9)
a x b x c x d = po 0.03; d o a, b, c (n=6); % values = d 4 a, b, c
Friedman’s test followed by Dunn’s test
a x b x e = po0.05; e o b o a (n=11); % values = e 4 b
Mann-Whitney test
d x e = p40.05; % values = p 40.05
c x e = p o0.05; e o c; % values = e 4 c.
Table 3 - Therapeutic approaches used in 28 patients with
acromegaly and gigantism.
G1
(n=16)
G2
(n=12)
Total
(n=28) %
Surgeryb+SRLsc 7 4 11 39.3
Surgery+radiotherapy+SRLs 4 1 5 17.8
Surgery+radiotherapy 1 2 3 10.7
SRL+cabergoline 1 2 3 10.7
SRL 2 1 3 10.7
Surgery+radiotherapy+SRLs+
cabergoline
0 1 1 3.6
Surgery 0 1 1 3.6
Radiotherapy 1 0 1 3.6
a: two of 30 patients were not treated, 1 died and another refused
treatment after diagnosis.
b: transphenoidal surgery
c: SRLs= somatostatin receptor ligands.
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during follow-up. Seventeen patients (56.7%) showed reduced
HDL-cholesterol levels, 11 patients (36.7%) showed increased
LDL-cholesterol levels, and 8 patients (26.7%) showed
increased triglyceride levels.
Postoperative complications were rarely described. One
patient had a cerebrospinal fluid leak, and 2 had transient
diabetes insipidus. Regarding clinical treatment, the most
common complaint was local pain and discomfort on the day
of administration of the medication. Three patients tended
to non-adherence to drug treatment; thus, octreotide was
replaced by lanreotide in the past year. Two patients com-
plained of abdominal pain and increased bowel movements.
The most common chronic complications observed among
the patients were analyzed. The thyroid was evaluated in
26 patients. Two cases of papillary cancer, 2 cases of follicular
adenomas and 2 cases of chronic autoimmune thyroiditis
were found. Colonoscopies were performed in 12 patients,
and 4 cases of colon polyps and 2 cases of diverticular disease
were found.
The cardiovascular assessments revealed that 12/30 patients
had hypertension, which was controlled with losartan,
amlodipine and atenolol. Among these patients, left ventri-
cular overload was diagnosed on ECG, and left ventricular
hypertrophy was diagnosed on conventional echocardio-
graphy.
Joint abnormalities, such as arthritis of the large joints and
spine, were observed in 25 patients. Two patients had carpal
tunnel syndrome, and 1 patient with gigantism had epi-
physiolysis of the femoral head.
’ DISCUSSION
This study is unique because it reports the diagnosis, treat-
ment and follow-up of patients with acromegaly/gigantism
outside of major referral medical centers in Brazil. Most of
our patients were from Uberaba and nearby municipalities,
and the resources available at the Clinics Hospital/UFTM
allowed them to be treated close to their homes, which
enabled regular monitoring and follow-up.
The incidence and prevalence of acromegaly in this region
are unknown. The analyzed cases span 23 years; objectively,
2-3 cases have been identified per year over the past 10 years,
indicating our service as a regional referral center that covers
a population of 700,000 inhabitants (13). These numbers
show that this region needs educational campaigns for early
recognition of the disease and its diagnosis.
Treatment of acromegaly/gigantism has advenced greatly
in recent decades, and studies indicate that the strict control
Table 6 - Growth hormone (GH) and insulin-like growth
factor 1 (IGF-1) concentrations in 20 treated patients at regular
follow-up.
GH (ng/mL) IGF-1 (ng/mL) G1 (n) G2 (n) Total
N %
o1 nl 8 3 11 55.0
o1 m 1 1 2 10.0
41 – o2.5 m 0 2 2 10.0
42.5 m 4 1 5 25.0
Table 5 - Therapeutic approach used in 20 patients in regular
follow-up.
G1 G2 Total
N %
Surgerya+SRLsb 7 2 9 45.0
Surgery+ratiotherapy+SRLs 2 1 3 15.0
SRLs+cabergoline 1 2 3 15.0
Surgery+radiotherapy+SRLs+cabergoline 0 1 1 5.0
SRLs 2 0 2 10.0
Surgery 0 1 1 5.0
Surgery+radiotherapy 0 1 1 5.0
a: transphenoidal surgery
b: SRLs= somatostatin receptor ligands.
Figure 1 - Correlations between pretreatment GH levels and
GH levels obtained after different treatment modalities: after
surgery (A); after surgery + radiotherapy (B); after surgery +
radiotherapy + SRLs (C); and after surgery + SRLs (D).
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of GH/IGF-1 levels reduces morbidity and mortality (5,10,11).
The subjects in the present study reflect this evolution. The
first patient was treated with radiotherapy alone. Until the
1990s, transphenoidal surgery was systematically followed
by radiotherapy. However, since the distribution of octreo-
tide by the SUS, radiotherapy in generally used only in
exceptional cases, as described by Jallad et al. (14).
Most of the acromegaly patients analyzed in the present
study were diagnosed late despite the fact that they dis-
played the classic symptoms and signs of the disease.
In most cases, the etiology was a pituitary macroadenoma,
which was on average diagnosed in the fifth decade of life.
These findings demonstrates the insidious nature of the
disease, which often leads to late diagnosis at an advanced
stage. In most cases, hyperproduction of GH began after
epiphyseal bone closure, as shown by the fact that the
acromegaly/gigantism ratio was 9:1. Acromegaly occurred
in both men and women, with a slight predominance in men
(1.3:1), consistent with reposts in the literature (15-17).
Most of our patients were primarily treated with surgery
(21/30). Current guidelines suggest that pituitary surgery
should be the primary approach to the disease due to its low
complication rate and to achieve debulking of the pituitary
tumor (6,7). Although Buchfelder & Schlaffer(18) reported a
74% success rate in achieving the GH/IGF-1 level control
parameters, the stricter current parameters (6,7) led Evran
et al. (19) and Sarkar et al. (20) to report success rates of
20-50% depending on the size of the tumor, the presence and
degree of cavernous sinus invasion, the surgical technique
employed and the surgeon’s skill. In contrast to these reports,
the strict control parameters were met in only 1 of the 21
patients in our study who underwent surgery; however, GH
levels were reduced by 53.1% (12.7-83.0%) and IGF-1 levels
were reduced by 69% (52.0-85.5%). Indeed, most of our
patients had macroadenomas, and the cavernous sinus was
involved in some cases. However, the surgical approach was
important to preserve vision and reduce the tumor mass.
Conventional radiotherapy was performed in 10 patients
and resulted in a considerable reduction in GH levels after
surgery in 9 patients (Table 4). However, the treatment was
not successful according to the current control parameters
(6,7). The addition of SRLs at individualized doses, which
has been shown in larger series to result in a success rate of
55.0% (15, 17), proved successful as complementary therapy.
Currently, 20 patients are undergoing follow-up (Table 6).
Other clinical treatment options such as administration of
cabergoline or lanreotide may increase the efficacy of treat-
ment among patients who reach the maximum dose of
octreotide or among noncompliant patients. Three patients
complained of pain at the injection site and were found to be
using the medication irregularly. Proper control was
obtained when the treatment was switched to lanreotide as
described by Strasburger et al. (21).
Another possible approach to treatment is the use of SRLs
as an initial approach in macroadenoma cases to reduce
the tumor size and allow better surgical outcomes (22-25).
Currently, some patients are receiving this treatment. This
approach can help the care provider decide on the appro-
priate time for surgery. Another point to consider is that the
co-secretion of prolactin observed in 4 patients allowed them
to obtain cabergoline from the SUS, which made the treat-
ment more effective (2,4).
According to the literature, cardiovascular events are the
main cause of death in acromegaly patients, indicating that
cardiovascular risk should be monitored (26,27). In the
present study, the percentage of subjects with hypertension,
impaired fasting glucose, diabetes and dyslipidemia was
similar to the percentage of such patients in the reports by
Alexopoulou et al. (28) and Dreval et al. (29). However, in the
9 patients who died during the course of our study, infections
were the main cause of unfavorable outcomes; this might
have been related to inadequate control of aspects of
acromegaly other than metabolic complications (26,27).
Based on the foregoing evaluation of our approach to the
diagnosis and treatment of acromegaly, both screening for
acromegaly and the treatment of chronic complications of
acromegaly need to be more systematic and multidisciplin-
ary. The importance of actively screening the general popula-
tion for thyroid cancer, colon cancer, and breast cancer is
supported by data from the literature (26,30,31) and has been
well accepted by patients who are convinced of the impor-
tance of early diagnosis for healing.
Although quality of life tests were not applied in this study
(7), we observed that one of the main factors that limited our
patients’ life-styles was joint and spinal injuries. These were
present in most of our patients. The changes that result in
such injuries are irreversible and result from increased GH
and IGF-1 levels over long periods of undiagnosed illness
(26). Greater involvement of colleagues in other specialties
following diagnosis could help provide early and preventive
treatment for various conditions involving the musculoske-
letal system.
The present study has some limitations. These include the
small size of the sample due to the rarity of the disease, the
difficulty of comparing different treatment modalities that
have changed over time and the need to analyze the data
according to the current criteria, which demand stricter
control of GH and IGF1 levels (6,7). On the other hand, this
study has the strength to show that the resources currently
available for the treatment of patients with acromegaly/
gigantism allow them to be properly treated in regional
reference centers.
We conclude that treatment of acromegaly represents a
multi-professional challenge and that in our environment,
it will be more effective and successful with earlier diagnosis,
improvement in surgical techniques, regular follow-up and
prompt availability of clinical treatment with SRL. In addi-
tion, multidisciplinary care of patients with chronic compli-
cations and the systematic search for data in pre-defined
protocols (32) will improve the quality of life and reduce the
cardiometabolic risk factors and mortality of patients with
acromegaly.
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